Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

Table 3 ALT response, by therapy group

ALT response N (%)	Group A Interferon and Ribavirin (n = 40)	Group B Ribavirin (n = 40)	Group C Placebo (n = 37)
On therapy¹	23 (58%)	9 (23%)	3 (8.1%)
End of treatment²	19 (48%)	4 (10%)	2 (5.4%)
End of follow up³	7 (18%)	1 (2.7%)	1 (2.5%)

¹normal ALT on at least two occasions with at least 1 month interval, p < 0.01 (Pearson Chi-square). ²normal ALT at week 24 and at least one month earlier, p < 0.01 (Pearson Chi-square). ³persistently normal ALT levels during 24 weeks follow up, p = 0.02 (Pearson Chi-square).

ISSN: 1471-230X